Enlivex Therapeutics is trading at $2.30, up 6% today as the stock rebounds from a dilution-driven selloff and reacts to a significant analyst price target hike.
- H.C. Wainwright recently raised its price target for the company to $80, sparking ongoing investor repositioning and a volatile recovery phase.
- The stock is bouncing back after trading 5.99% down in after-hours on August 3, a move driven by profit-taking following the bullish analyst call and a prior capital raise.
- Current market activity suggests a stabilization in sentiment as investors weigh the aggressive price target against recent share dilution.